| 產品名稱 | U-937 |
|---|---|
| 商品貨號 | B165900 |
| Organism | Homo sapiens, human |
| Tissue | Pleura/pleural effusion, lymphocyte, Myeloid |
| Product Format | frozen |
| Morphology | monocyte |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | histiocytic lymphoma |
| Age | 37 years |
| Gender | male |
| Ethnicity | Caucasian |
| Applications | This cell line is suitable as a transfection host |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma. |
| Clinical Data | 37 years Caucasian male The U-937 cell line was derived by Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a patient with histiocytic lymphoma. |
| Receptor Expression | complement (C3) |
| Genes Expressed | lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA) |
| Cellular Products | lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA) |
| Comments | Studies since 1979 have shown that U-937 cells can be induced to terminal monocytic differentiation by supernatants from human mixed lymphocyte cultures,
The cells are negative for immunoglobulin production and Epstein-Barr virus expression.
The cells express the Fas antigen, and are sensitive to TNF and anti-Fas antibodies.
In 1994, PCR and cytogenetic analyses showed that a number of stocks of U-937 were contaminated with the human myeloid leukemia cell line, K-562.
In the earliest stocks available, the level of contamination was 0.6%.
Distribution was discontinued in March 1994, except if required for patent purposes.
Anyone who wishes to receive a sample of this original material should contact the Head of the ATCC Patent Depository.
A stock of CRL-1593 found to be free of K-562 was propagated continuously for 8 weeks and tested weekly by PCR.
Distribution and seed stocks give DNA profiles characteristic of U-937 only.
Such preparations are now offered as authentic U-937 (ATCC CRL-1593.2) and are believed to be free of second subpopulations. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 105 viable cells/mL. Corning® T-75 flasks (catalog #431464) are recommended for subculturing this product.
Interval: Maintain cell density between 1 X 105 and 2 X 106 viable cells/mL.
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density) |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile | Amelogenin: X CSF1PO: 12 D13S317: 10,12 D16S539: 12 D5S818: 12 D7S820: 9,11 THO1: 6, 9.3 TPOX: 8,11 vWA: 14, 15 |
| Name of Depositor | H Koren |
| Deposited As | Homo sapiens |
| Year of Origin | 1974 |
| References | Ralph P, et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. PubMed: 1083890 . Gene expression during normal and malignant differentiation. London: Academic Press; 1985. . International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980. Koren HS, et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. PubMed: 450085 Gidlund M, et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. PubMed: 7266653 Olsson I, et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. PubMed: 6315218 Morimoto H, et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. PubMed: 7684321 Giovannangeli C, et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target. Proc. Natl. Acad. Sci. USA 94: 79-84, 1997. PubMed: 8990164 Brigino E, et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA 94: 3178-3182, 1997. PubMed: 9096366 Reid YA, et al. Cell Line Cross-contamination of U-937. J. Leukocyte Biol. 57: 804, 1995. PubMed: 7759961 Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17: 565-577, 1976. PubMed: 178611 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
